NHANCE Trademark

Trademark Overview

On Tuesday, August 28, 2012, a trademark application was filed for NHANCE with the United States Patent and Trademark Office. The USPTO has given the NHANCE trademark a serial number of 79120504. The federal status of this trademark filing is SECTION 71 ACCEPTED as of Saturday, May 11, 2024. This trademark is owned by arGEN-X B.V.. The NHANCE trademark is filed in the Pharmaceutical Products and Computer & Software Services & Scientific Services categories with the following description:

[ Medicines, namely, antibodies for the treatment of infectious diseases and inflammation and for use in oncology; medicines for the treatment of infectious diseases and inflammation and for use in oncology; medicines for autoimmune inflammatory disorders ]

Research and development in the field of biotechnology; research into new drugs and development of drugs; providing scientific and technical research services in the field of biotechnology and genetics, and research and design relating thereto; [ industrial analysis in the nature of biochemical analyses and research services in the field of biotechnology; laboratories, namely, medical laboratory services; ] providing medical and scientific research information and advice in the field biotechnology
nhance

General Information

Serial Number79120504
Word MarkNHANCE
Filing DateTuesday, August 28, 2012
Status706 - SECTION 71 ACCEPTED
Status DateSaturday, May 11, 2024
Registration Number4434350
Registration DateTuesday, November 19, 2013
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, September 3, 2013

Trademark Statements

Goods and Services[ Medicines, namely, antibodies for the treatment of infectious diseases and inflammation and for use in oncology; medicines for the treatment of infectious diseases and inflammation and for use in oncology; medicines for autoimmune inflammatory disorders ]
Pseudo MarkENHANCE
Goods and ServicesResearch and development in the field of biotechnology; research into new drugs and development of drugs; providing scientific and technical research services in the field of biotechnology and genetics, and research and design relating thereto; [ industrial analysis in the nature of biochemical analyses and research services in the field of biotechnology; laboratories, namely, medical laboratory services; ] providing medical and scientific research information and advice in the field biotechnology

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status CodeG - NOT AVAILABLE
Class Status DateMonday, January 13, 2020
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE
International Class042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software.
US Class Codes100, 101
Class Status Code6 - Active
Class Status DateWednesday, November 28, 2012
Primary Code042
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party Nameargenx, besloten vennootschap met beperk
Party Type31 - New Owner After Registration
Legal Entity Type99 - Other
AddressGent (Zwijnaarde) B-9052
BE
Party Nameargenx, Societas Europaea
Party Type30 - Original Registrant
Legal Entity Type16 - Limited Liability Company
AddressNL
Party NamearGEN-X B.V.
Party Type20 - Owner at Publication
Legal Entity Type16 - Limited Liability Company
AddressNL
Party NamearGEN-X B.V.
Party Type10 - Original Applicant
Legal Entity Type16 - Limited Liability Company
AddressNL

Trademark Events

Event DateEvent Description
Wednesday, November 28, 2012NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, November 22, 2012SN ASSIGNED FOR SECT 66A APPL FROM IB
Tuesday, December 4, 2012APPLICATION FILING RECEIPT MAILED
Thursday, December 20, 2012ASSIGNED TO EXAMINER
Friday, December 28, 2012NON-FINAL ACTION WRITTEN
Saturday, December 29, 2012NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
Wednesday, January 9, 2013REFUSAL PROCESSED BY MPU
Wednesday, January 9, 2013NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
Thursday, February 14, 2013REFUSAL PROCESSED BY IB
Friday, March 1, 2013CHANGE OF NAME/ADDRESS REC'D FROM IB
Tuesday, July 9, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 9, 2013TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, July 9, 2013CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, July 10, 2013TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, July 11, 2013APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, July 26, 2013ASSIGNED TO LIE
Friday, July 26, 2013LAW OFFICE PUBLICATION REVIEW COMPLETED
Wednesday, August 14, 2013NOTICE OF PUBLICATION
Wednesday, August 28, 2013NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Wednesday, August 28, 2013NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Tuesday, September 3, 2013PUBLISHED FOR OPPOSITION
Sunday, September 15, 2013NOTIFICATION PROCESSED BY IB
Tuesday, November 19, 2013REGISTERED-PRINCIPAL REGISTER
Wednesday, February 19, 2014FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Thursday, February 20, 2014FINAL DISPOSITION PROCESSED
Thursday, February 20, 2014FINAL DISPOSITION NOTICE SENT TO IB
Thursday, March 6, 2014FINAL DECISION TRANSACTION PROCESSED BY IB
Monday, July 21, 2014NEW REPRESENTATIVE AT IB RECEIVED
Thursday, May 24, 2018CHANGE OF OWNER RECEIVED FROM IB
Friday, December 4, 2015CHANGE OF NAME/ADDRESS REC'D FROM IB
Thursday, September 1, 2016CHANGE OF NAME/ADDRESS REC'D FROM IB
Thursday, December 14, 2017CHANGE OF NAME/ADDRESS REC'D FROM IB
Thursday, October 4, 2018NEW REPRESENTATIVE AT IB RECEIVED
Tuesday, November 19, 2019TEAS SECTION 71 & 15 RECEIVED
Tuesday, January 7, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, January 13, 2020CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Monday, January 13, 2020REGISTERED - PARTIAL SEC. 71 ACCEPTED & SEC. 15 ACK.
Monday, January 13, 2020NOTICE OF ACCEPTANCE OF SEC. 71 & 15 - E-MAILED
Thursday, June 25, 2020NEW REPRESENTATIVE AT IB RECEIVED
Sunday, September 13, 2020PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Wednesday, September 30, 2020GENERIC MADRID TRANSACTION CREATED
Thursday, October 1, 2020GENERIC MADRID TRANSACTION SENT TO IB
Saturday, November 7, 2020PARTIAL INVALIDATION PROCESSED BY THE IB
Friday, September 16, 2022INTERNATIONAL REGISTRATION RENEWED
Saturday, October 1, 2022NEW REPRESENTATIVE AT IB RECEIVED
Friday, October 21, 2022TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, October 21, 2022TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, October 21, 2022ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, October 21, 2022TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, October 21, 2022TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, October 21, 2022APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Saturday, November 19, 2022COURTESY REMINDER - SEC. 71 (10-YR) E-MAILED
Friday, September 15, 2023TEAS SECTION 71 RECEIVED
Saturday, May 11, 2024NOTICE OF ACCEPTANCE OF SEC. 71 - E-MAILED
Tuesday, September 3, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Tuesday, May 7, 2024CASE ASSIGNED TO POST REGISTRATION PARALEGAL
Saturday, May 11, 2024REGISTERED-SEC.71 ACCEPTED
Tuesday, September 3, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Tuesday, September 3, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, September 3, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Tuesday, September 3, 2024TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Tuesday, September 3, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Saturday, March 29, 2025INVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE
Sunday, January 12, 2025PARTIAL INVALIDATION OF REG EXT PROTECTION CREATED
Friday, October 11, 2024NEW REPRESENTATIVE AT IB RECEIVED

Related Keywords

nhance research biotechnology field medicines services development medical scientific drugs providing